Pancreatic Cancer Research

ResearcherTel Aviv UniversityActive in the last 2 years

Nir Lubezky

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9355-4405; OpenAlex author ID A5085260720. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
13
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 11

  1. Intraoperative Management Strategies for Unresectable Pancreatic Adenocarcinoma: A Propensity-Weighted Cohort Study. Co-author DOI 10.1177/00031348261499335↗
  2. The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreatic Cancer Patients Treated with Neoadjuva… Last author DOI 10.3390/jcm13175206↗
  3. Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? Last author DOI 10.3390/cancers15113049↗
  4. Prognostic significance of pancreatic fistula and postoperative complications after pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surge.2019.07.003↗
  5. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-020-08469-8↗
  6. ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy. Last author DOI 10.1245/s10434-020-08495-6↗
  7. MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis. Co-author DOI 10.18632/oncotarget.26804↗
  8. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Last author DOI 10.1016/j.ejso.2018.07.057↗
  9. Unique cellular interactions between pancreatic cancer cells and the omentum. Co-author DOI 10.1371/journal.pone.0179862↗
  10. Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology… First author DOI 10.1186/s12957-016-0983-5↗
  11. Pancreatic cancer: surgery is a feasible therapeutic option for elderly patients. Co-author DOI 10.1186/1477-7819-9-10↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guy Lahat · 9 shared papers, 2011–2026 · strength 1.08
  2. Joseph M. Klausner · 8 shared papers, 2016–2024 · strength 0.90
  3. Alex Barenboim · 5 shared papers, 2018–2024 · strength 0.75
  4. Ido Wolf · 4 shared papers, 2016–2023 · strength 0.40
  5. Ido Nachmany · 5 shared papers, 2011–2020 · strength 0.36
  6. Lior Orbach · 1 shared paper, 2026 · strength 0.36
  7. Talia Golan · 2 shared papers, 2020 · strength 0.29
  8. Yossi Maman · 1 shared paper, 2023 · strength 0.18
  9. Eran Nizri‏ · 2 shared papers, 2016–2019 · strength 0.16
  10. Uri Neeman · 1 shared paper, 2020 · strength 0.11
  11. Moran Lemberger · 1 shared paper, 2019 · strength 0.10
  12. Valerya Feygenzon · 1 shared paper, 2017 · strength 0.08
  13. Josef M. Klausner · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.